Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nektar Therapeutics NKTR

Healthcare Biotechnology
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions;... see more

Current News (NDAQ:NKTR)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire 5 days ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

PR Newswire November 8, 2025

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

PR Newswire November 6, 2025

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

PR Newswire October 30, 2025

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

PR Newswire October 28, 2025

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

PR Newswire October 22, 2025

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

PR Newswire September 18, 2025

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

PR Newswire September 9, 2025

Nektar Therapeutics to Participate in Two Investor Conferences in September

PR Newswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:NKTR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NKTR)

When the MACD WILL TURN POSITIVE

Check the money comes in.....GLTA
Form001 - 1 day ago

Low volume, low volatility

I like that.
Form001 - 1 day ago

Nektar is a great momentum stock to buy…

https://finance.yahoo.com/news/heres-why-nektar-therapeutics-nktr-170004640.html
Form001 - 1 day ago

Still undervalued..

https://finance.yahoo.com/news/nektar-therapeutics-nktr-still-undervalued-121210586.html
Form001 - 2 days ago

Like the trading

Low volume.
Form001 - 2 days ago

Positive news about 2 new employées.

Options at actual price.....GLTA
Form001 - 2 days ago
View more Bullboard ››

Lithium Ionic Corp

Lithium Ionic Corp

Lithium Ionic Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of lithium ...
View More »